BCM
CAPR icon

Boxer Capital Management’s Capricor Therapeutics CAPR Stock Holding History

Boxer Capital Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.6M Buy
1,395,156
+805,156
+136% +$24.4M 2.53% 11
2026
Q1 		$17.9M Buy
590,000
+265,000
+82% +$7.06M 2.35% 10
2025
Q4 		$9.38M Buy
+325,000
New +$4.24M 2.05% 16

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Boxer Capital Management's CAPR Position: Q2 2026 in Review

Boxer Capital Management increased its Capricor Therapeutics (CAPR) stake by 136% in Q2 2026, buying an estimated $24.4M and bringing the position to 1,395,156 shares worth $33.6M. The position accounts for 2.53% of the portfolio, ranked #11.

Boxer Capital Management first reported a position in CAPR in Q4 2025 and has held it in 3 quarters since. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Boxer Capital Management held 1,395,156 shares of Capricor Therapeutics worth $33.6M as of Q2 2026.
  • Boxer Capital Management bought 805,156 Capricor Therapeutics shares in Q2 2026, an estimated $24.4M.
  • Capricor Therapeutics made up 2.53% of Boxer Capital Management's portfolio in Q2 2026, its #11 holding.
  • Boxer Capital Management first reported a position in Capricor Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Boxer Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.